Public-registry trials using 100 mg/day that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) | Transposon Therapeutics, Inc. | Progressive Supranuclear Palsy | PHASE2 | 14 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →